

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 February 2024 (01.02.2024)



(10) International Publication Number
WO 2024/026488 A3

- (51) **International Patent Classification:**
A01K 67/027 (2024.01) *C12N 15/85* (2006.01)
- (21) **International Application Number:**
PCT/US2023/071261
- (22) **International Filing Date:**
28 July 2023 (28.07.2023)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/369,842 29 July 2022 (29.07.2022) US
- (71) **Applicant: REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).
- (72) **Inventors: MURPHY, Andrew J.**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **TANG, Yajun**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

maceticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **FANG, Qing**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **PRAGGASTIS, Maria**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **ZHONG, Jun**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **CYGNAR, Katherine**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **MUJICA, Alexander O.**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(74) **Agent: WU, Rita**; FisherBroyles/Regeneron/RW, 79 Willowleaf Drive, Littleton, Colorado 80127 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,

(54) **Title:** NON-HUMAN ANIMALS COMPRISING A MODIFIED TRANSFERRIN RECEPTOR LOCUS

	Official Symbol	NCBI Gene ID	RefSeq mRNA ID	UniProt ID	Genomic Assembly	Location
Mouse	Tfrc	22042	NM_001357298.1	Q62351	GRCh39	Chr16:32427714-32451612(+)
Human	TFR	7037	NM_001128148.3	P02786	GRCh38.p14	Chr3:196049284-196082090(-)

	Genome Build	Start	End	Length (bp)
5' mouse arm	GRCh38/mm10	chr16:32,548,579	32,614,239	65,661
Human Insert	GRCh38	chr3:196,075,456	chr3:196,049,415	26,240
3' mouse arm	GRCh38/mm10	chr16:32,630,774	Chr16:32,659,232	28,459

FIGURE 1A

(57) **Abstract:** Non-human animal cells and non-human animals comprising a humanized *Tfrc* gene, e.g., at an endogenous *Tfrc* locus, and methods of using such non-human animal cells and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized *Tfrc* gene express a human TfR protein or fragments thereof. Non-human animal cells and non-human animals comprising a humanized *Tfrc* gene and a knockout mutation in a *Gaa* gene, e.g., at an endogenous *Gaa* locus, and methods of using such non-human animal cells and non-human animals are also provided. Such animals are useful to screen anti-human-TfR binding protein based therapies of, e.g., Pompe disease.

[Continued on next page]

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

04 April 2024 (04.04.2024)